Short-term efficacy and adverse events of intensity-modulated radiotherapy combined with chronomodulated chemotherapy for locally advanced nasopharyngeal carcinoma

Hang Jiang; Feng Jin; Weili WU; Yuanyuan LI; Jinhua Long; Xiuyun Gong; Xiaoxiao Chen; Jiaying Gan; Zhuoling LI

Return

Short-term efficacy and adverse events of intensity-modulated radiotherapy combined with chronomodulated chemotherapy for locally advanced nasopharyngeal carcinoma

VernacularTitle: 调强放疗联合时辰化疗治疗局部进展期鼻咽癌的近期疗效及不良反应
Author: Hang JIANG ¹ ; Feng JIN ¹ ; Weili WU ¹ ; Yuanyuan LI ¹ ; Jinhua LONG ¹ ; Xiuyun GONG ² ; Xiaoxiao CHEN ¹ ; Jiaying GAN ¹ ; Zhuoling LI ¹
Author Information

1. Department of Oncology of The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China
2. The Affiliated Cancer Hospital of Guizhou Medical University, Department of Head and Neck Oncology/Guizhou Cancer Hospital, Guiyang 550004, China
Publication Type:Journal Article
Keywords: Nasopharyngeal carcinoma; Chronomodulated chemotherapy; Intensity-modulated radiotherapy; Adverse events; Short-term efficacy
From: Chinese Journal of Radiological Medicine and Protection 2019;39(11):813-819
CountryChina
Language:Chinese
Abstract: Objective:To compare the adverse events, immune status, and short-term efficacy between chronomodulated chemotherapy (CCR) and routine chemotherapy (RCR) combined with intensity modulated radiotherapy (IMRT)in the treatment of patients with locally advanced nasopharyngeal carcinoma.
Methods:A total of 159 patients with newly diagnosed locally advanced nasopharyngeal carcinoma were randomized into the CCR group and the RCR group to evaluate the short-term efficacy and adverse events.
Results:No significant difference was found in CR, PR, SD, and PD between the CCR group and the RCR group (P>0.05), and no significant difference was observed in the response rate (CR+ PR) between the two groups (P>0.05). The incidence of leukopenia(Z=-2.222, P<0.05), neutropenia(Z=-1.999, P<0.05), vomiting(Z=-2.298, P<0.05), and oral mucositis(Z=-3.571, P<0.05)of the CCR group was lower than those of the RCR group with statistical significance. The CD16+ 56+ lymphocyte cell count was higher in the CCR group than that in the RCR group(Z=-2.332, P<0.05).
Conclusions:As a novel invention, CCR combined with IMRT can reduce the incidence and severity of treatment-related adverse events and improve immune status without diminishing clinical efficacy, therefore deserving clinical application.